Skip to main content
Premium Trial:

Request an Annual Quote

Max Planck Institute to Use Illumina s Genotyping Platform to Study Depression, Anxiety

NEW YORK, Sept. 20 (GenomeWeb News) - Researchers at the Max Planck Institute of Psychiatry in Munichwill use Illumina's whole-genome arrays to study the genetic basis of depression and anxiety, Illumina said today.

 

In the first part of the project, the scientists will genotype a large number of samples using Illumina's Sentrix Human-1 BeadChip. In the second phase, they plan to use the company's new Sentrix BeadChip to analyze over 250,000 TagSNPs derived from data of the International HapMap project.

 

The aim of the study is to identify genetic variations associated with depression and anxiety and to determine their impact on disease pathogenesis and response to psychotropic drugs.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.